logo

Nabriva Therapeutics (NBRV)



Trade NBRV now with
  Date
  Headline
6/21/2019 7:07:41 AM Nabriva Therapeutics To Present Data At ASM Microbe On Potential Of Lefamulin
6/19/2019 7:07:24 AM Nabriva Therapeutics Submits Type A Meeting Request To FDA For Intravenous CONTEPO For Injection
5/14/2019 6:47:48 AM Wedbush Is Raising Nabriva Therapeutics (NBRV) FY19 Rev. Estimate To 6.2 M From 3.8 M
5/14/2019 6:47:36 AM Wedbush Is Lowering Nabriva Therapeutics (NBRV) Q4 19 Rev. Estimate To 1.9 M From 2.0 M
5/14/2019 6:47:25 AM Wedbush Is Raising Nabriva Therapeutics (NBRV) Q3 19 Rev. Estimate To 1.8 M From 0.3 M
5/14/2019 6:47:13 AM Wedbush Is Cutting Nabriva Therapeutics (NBRV) Q2 19 Rev. Estimate To 0.9 M From 1.1 M
5/14/2019 6:46:52 AM Wedbush Is Raising Nabriva Therapeutics (NBRV) FY19 Estimate To -1.14 From -1.18
5/14/2019 6:46:33 AM Wedbush Is Increasing Nabriva Therapeutics (NBRV) Q3 19 Estimate To -0.25 From -0.26
5/14/2019 6:46:20 AM Wedbush Is Increasing Nabriva Therapeutics (NBRV) Q2 19 Estimate To -0.33 From -0.34
4/30/2019 9:02:58 PM Nabriva Therapeutics Gets CRL From FDA On NDA For Intravenous CONTEPO For Injection
1/14/2019 7:09:15 AM Nabriva Therapeutics Updates On PDUFA Date For Intravenous CONTEPO
12/21/2018 7:04:45 AM Nabriva Therapeutics Announces Closing Of Up To $75 Mln Term Loan
12/20/2018 7:04:11 AM Nabriva Therapeutics Submits NDA For Lefamulin To Treat Community-Acquired Bacterial Pneumonia In Adults
11/6/2018 7:12:19 AM Nabriva Therapeutics Q3 Net Loss $52.8 Mln Or $0.90/Shr Vs Loss Of $22.3 Mln Or $0.79/Shr Last Year
9/28/2018 7:12:00 AM Nabriva Therapeutics To Present Data At ID Week Demonstrating Potential Of Lefamulin For CABP And CONTEPO
8/9/2018 7:19:07 AM Nabriva Therapeutics Q2 Net Loss $17.8 Mln Or $0.44/shr Vs Loss Of $14.6 Mln Or $0.54/shr Last Year
7/26/2018 8:07:35 PM Nabriva Therapeutics Prices Public Offering Of 18.18 Mln Shares At $2.75/shr